Clinical Trial Imaging Market Growth & Trends
The global clinical trial imaging market size is expected to reach USD 1.97 billion by 2030, registering a CAGR of 7.60% during the forecast period, according to a new report by Grand View Research, Inc. Increasing research and development spending to discover new drugs and therapies to treat chronic diseases is propelling the industry growth. Images obtained from the internal examination of the body are used to determine drug activity. Clinical trial imaging provides rapid, detailed, and accurate screening. The need for clinical trial imaging is rapidly increasing in all phases of trials. Medical imaging in clinical trials is used as a primary, quantitative, and surrogate biomarker.
The clinical trial design includes selecting patient population, stratification based on biomarkers, different methods for allocation treatments, choosing efficient and reliable endpoints and validation of surrogate endpoints, calculating sample size, trial simulations, adaptive trial set-up, statistical and interim analysis, and assisting clients to deal with regulatory authorities such as EMA and FDA to discuss study design or defend study results.
Market players provide analytical testing services, pharmacokinetic, reading, and pharmacodynamics services for enhanced clinical development. IXICO offers advanced technologies for catalyzing clinical trials in neuroscience. Imaging biomarkers by the company help in measuring the safety and effectiveness of therapies used for neuro-imaging. Imaging biomarkers are effective in radiological reads. This provides the reading of MRI scans for central neuro to enhance the assessment of ongoing monitoring of drug safety and subject eligibility
Request a free sample copy or view report summary:
Clinical Trial Imaging Market Report
Clinical Trial Imaging Market Report Highlights
- Project and Data Management Services held the largest share in 2023 due to the growing requirement for data management and workflow for clinical trial imaging
- Operational imaging services held a significant share in 2023 and include imaging modalities such as MRI, CT scan, Ultrasound, Optical Coherence Tomography (OCT), X-rays, and others
- The oncology segment held the largest share in 2023. High prevalence of cancer cases and the constant need for new and innovative therapies to treat various types of cancer are expected to fuel the market growth.
- CROs held the largest share in 2023 due to increasing investments in the field of research and development, snowballing outsourcing activities by the pharmaceutical and biotechnology companies to cut down the cost and time, and patent expiration
- North America dominated this market with the largest share in 2023 due to the increasing geriatric population, along with chronic diseases and growing demand for treatment options.
